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Stuart A Bell and Catrin Tudur Smith*Abstract
Objectives: To provide a comprehensive characterisation of rare disease clinical trials registered in ClinicalTrials.gov,
and compare against characteristics of trials in non-rare diseases.
Design: Registry based study of ClinicalTrials.gov registration entries.
Methods: The ClinicalTrials.gov registry comprised 133,128 studies registered to September 27, 2012. By annotating
medical subject heading descriptors to condition terms we could identify rare and non-rare disease trials. A total of
24,088 Interventional trials registered after January 1, 2006, conducted in the United States, Canada and/or the
European Union were categorised as rare or non-rare. Characteristics of the respective trials were extracted and
summarised with comparative statistics calculated where appropriate.
Main outcome measures: Characteristics of interventional trials reported in the database categorised by rare and
non-rare conditions to allow comparison.
Results: Of the 24,088 trials categorised 2,759 (11.5%) were classified as rare disease trials and 21,329 (88.5%) related
to non-rare conditions. Despite the limitations of the database we found that rare disease trials differed to non-rare
disease trials across all characteristics that we examined. Rare disease trials enrolled fewer participants (median 29
vs. 62), were more likely to be single arm (63.0% vs. 29.6%), non-randomised (64.5% vs. 36.1%) and open label
(78.7% vs. 52.2%). A higher proportion of rare disease trials were terminated early (13.7% vs. 6.3%) and proportionally
fewer rare disease studies were actively pursuing, or waiting to commence, enrolment (15.9% vs. 38.5%).
Conclusion: Rare disease interventional trials differ from those in non-rare conditions with notable differences in
enrolment, design, blinding and randomisation. However, clinical trials should aim to implement the highest trial
design standards possible, regardless of whether diseases are rare or not.
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In the United States (US), a rare disease is defined as
having a prevalence of fewer than 200,000 affected indi-
viduals [1]. Across the European Union (EU) the defin-
ition is that the condition affects not more than 5 in
10,000 individuals [2]. The Orpha.net database, which
provides a reference portal for information on rare dis-
eases, identifies approximately 7,000 rare diseases [3].
It is often assumed that clinical trials in rare condi-
tions differ from those of non-rare conditions. However,* Correspondence: cat1@liverpool.ac.uk
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article, unless otherwise stated.the extent and nature of these differences is not well
understood. Kesselheim et al. provide one comparative
survey exploring pivotal trials in orphan versus non-
orphan drug approval [4]. These authors characterised a
number of preapproval trials highlighting differences in
enrolment, randomisation, blinding, comparison groups
and primary outcomes. However, their survey was limited
to oncology trials that supported successful drug ap-
provals. The approach of Kesselheim et al. was extended
by Orfali et al. to clinical trials of non-oncological orphan
drugs compared with those of non-orphan drugs [5].
These authors concluded that characteristics such as
blinding, randomisation and placebo control were similarCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 Example of the MeSH database table used to
identify conditions
ROW_ID MESH_TERM MESH_ID
1 Sarcoma, Ewing D012512
2 Ewing Sarcoma D012512
3 Ewing's Tumor D012512
4 Sarcoma, Ewing's D012512
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methodological flaws in their approach likely ‘blunted’ dif-
ferences observed between the cohorts [6]. Further studies
have explored the pivotal trials and complete dossiers of
orphan medicinal products approved by the European
Medicines Agency (EMA); although neither publications
provided contrasting characteristics for non-orphan
products [7,8]. To our knowledge no large scale compara-
tive survey has been undertaken to contrast rare disease
trials with those in other conditions.
ClinicalTrials.gov provides a public access registry and
results database recording clinical studies on human par-
ticipants. It provides a global registry of both publicly and
privately supported trials. The registry is widely used cur-
rently containing close to 150,000 research studies. Data
can be downloaded across all registered studies and has
been used to explore various characteristics of clinical trials
[9,10]. Recently, the usability of the ClinicalTrials.gov data-
set has been extended for research purposes through the
development of the Aggregate Analysis of ClinicalTrials.
gov (AACT) database [11]. Research using the AACT data-
base to conduct surveys of clinical trials across different
clinical specialties is now emerging. Particular examples
include Califf et al. who provide specific characterisations
of interventional trials in the areas of oncology, cardio-
vascular and mental health and Hirsch et al. who also
characterise interventional oncology trials with further
sub-categorisation [12,13].
Our objectives were to use the AACT database to pro-
vide a comprehensive characterisation of rare disease
clinical trials registered in ClinicalTrials.gov. Further, we
wished to compare these characteristics against those of
trials in other, non-rare, conditions.
Methods
The AACT database
On July 25, 2013 we downloaded the 2012 AACT data-
base from the CTTI website [14]. The database comprised
of 133,128 clinical studies registered with ClinicalTrials.
gov to September 27, 2012. The key feature of the design,
structure and purpose of the AACT database are detailed
in Tasneem et al. and the corresponding website [11,14].
When submitting trials to ClinicalTrials.gov data submit-
ters are requested to provide the diseases and clinical con-
ditions under study as Medical Subject Heading (MeSH)
terms. Further, ClinicalTrials.gov uses an algorithm pro-
vided by the National library of Medicine (NLM) to anno-
tate additional MeSH terms to a given study [11].
The same condition may exist in ClinicalTrials.gov
under various synonyms. To help categorise conditions
we downloaded the 2013 MeSH thesaurus and the 2013
supplementary concept records [15,16]. Each record
within these sources contained a MeSH Id, a preferred
descriptor name and the names of related concepts whichprovided synonyms and lexical variations of the preferred
descriptor. Table 1 shows an example for Ewing Sarcoma
of the information extracted from these sources. In this
case ‘Sarcoma, Ewing’ is the preferred MeSH descriptor
and the remaining entries are potential variations all
mapped to the same MeSH Id.
For the 133,128 clinical studies in the AACT database
a total of 211,063 user submitted conditions had been
provided. Of these 144,871 (68.6%) could be annotated
with a MeSH Id. A further 268,796 MeSH terms had
been annotated to these trials by the NLM algorithm;
these were also matched to their relevant MeSH Id.
Identification of rare diseases
To subgroup studies into rare and non-rare diseases it
remained to identify MeSH Id’s related to rare diseases.
To identify these we consolidated information from
three sources. Firstly, ClinicalTrials.gov identifies trials
involving rare diseases within the ‘By Topic’ display
option. This listed a total of 1,430 rare diseases based on
the US definition. Secondly, we downloaded documenta-
tion entitled ‘Rare Disease and Cross References’ from
OrphanData.org containing 6,767 diseases classified as
rare within the EU [17]. As a final resource we extracted
rare conditions from the alphabetical lists provided by
the Office of Rare Diseases Research [18]. This provided
an additional 6,526 rare disease condition names. Upon
removing duplicates a total of 11,959 rare disease names,
synonyms and lexical variations remained. Using a com-
bination of lookups, pattern matching and manual
search a total of 6,389 (54%) rare disease names, syno-
nyms and lexical variations were matched to their rele-
vant MeSH Id. In total 4,516 unique MeSH Id’s were
used and identified as rare. Whilst 54% may seem a low
percentage, many of the 11,959 diseases listed are
extremely rare and only recently identified. For quality
assessment purposes we performed a Targeted Search of
ClinicalTrials.gov using each of the 11,959 disease names
as conditions. The total number of studies returned from
each search was recorded. For example a targeted search
using ‘Krabbe disease’ as the condition name returned 19
studies that may relate to this disease. In total 194,226
studies were returned via this search method, of which,
177,333 (91%) where contained within the 6,389 of condi-
tions we identified as having MeSH Id’s.
Figure 1 Identification of the comparison data sets (shaded boxes show the final data sets used in analysis.
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Final datasets for comparison (Figure 1) were created using
the annotated MeSH Id’s following a number of restric-
tions. Briefly, of the 133,128 studies in the database only
interventional studies were eligible for inclusion leaving
108,113 studies. Attention was restricted to trials first reg-
istered on or after January 1, 2006 leaving 86,812 studies.
Our goal was to characterise trials on patients with
rare diseases thus any trials accepting healthy volunteers
were excluded leaving 66,574 studies. Finally, the condi-
tions identified as rare are only rare in specific countries.
We excluded any trial with participating centres regis-
tered outside the US, EU or Canada leaving 43,986 stud-
ies, of these 27,966 trials had a complete complement of
MeSH Id’s allowing for categorisation.
A trial was identified as a non-rare disease trial if none
of its annotated MeSH Id’s had been identified as rare. A
total of 21,329 trials had no rare MeSH Id’s; 6,637 trials
had at least 1 rare disease MeSH Id. Trials were finally
classified as rare based on the user submitted MeSH Id’s
only. We classified a trial as a rare disease trial if all user
submitted MeSH Id’s were rare; this left 2,759 rare
disease trials.
Analytical methods
Prior to analysis certain missing characteristics were
inferred. When a trial relates to a single group with the
interventional model described as single assignment the
trial was designated as non-randomised with open
blinding [12].
Descriptive statistics were used to characterise the
identified datasets. For categorical data, frequencies and
percentages are stated; for continuous data, medians and
interquartile ranges (IQR) are stated. We did not have
any pre-specified hypotheses in this study and have not
presented results from statistical tests. Between group
differences in percentages are presented for categorical
characteristics. The 95% confidence intervals for the be-
tween group difference was calculated using the Wilson
procedure without continuity correction. R 2.13 was
used for all statistical analysis [19].
Ethical approval
This analysis of existing publicly available data relates to
clinical trials and their characteristics rather than human
participants. Ethical approval was not required.
Results
From January 1, 2006 to September 27, 2012 a total of
2,759 trials were identified as relating to rare diseases
and 21,329 trials as relating to non-rare diseases. The
2,759 rare disease trials include only 430 unique MeSH
Id’s for the conditions under study. This corresponds to
only 9.5% (430/4516) of the rare disease unique MeSHId’s identified. The labels used in the clinicaltrials.gov
database are in some sense weakly defined and can often
be interpreted differently by different users which might
impact the validity of results presented here.
Trial characteristics
Basic characteristic of trials in the identified datasets are
shown in Table 2. The meaning of characteristics is gen-
erally self-evident, although exact definitions for certain
characteristics are given in the text. Further definitions
of characteristics can be found in the ClinicalTrials.gov
draft Protocol Data Element Definitions and e-appendix
1 of Califf et al. [12,20].
The proportion of trials which are in rare diseases has
decreased over time based on the year enrolment to
protocol began (Table 2). The overall recruitment status
also suggests a higher proportion of rare disease trials
are active but not yet recruiting or have terminated early
with fewer currently recruiting.
Study duration is defined as the date from which en-
rolment begins until the final date on which data was, or
is anticipated to be, collected. The median study dur-
ation, in years, is longer in rare disease trials (median,
3.2[IQR 2.0-4.9] vs. 2.3[1.3, 3.8]).
Participant eligibility characteristics based on gender
and age are more inclusive in rare disease trials with a
higher proportion of rare disease trials that included both
genders (93.6% vs. 86.0%), paediatric patients (20.6% vs.
11.1%) and elderly patients (86.4% vs. 83.2%). It should be
noted that this is only enrolment criteria and not data on
those who actually participated.
In ClinicalTrials.gov a trial can report either actual or
expected numbers recruited but not both. The antici-
pated number of patients to be recruited in rare trials is
less than that of non-rare disease trials (median, 41[IQR
24–74] vs. 76[40–182]). Similarly, the actual number of
patients recruited is less for rare disease trials than in
non-rare trials (29[12–60] vs. 62[27–175]). For rare dis-
ease trials the median actual enrolment is 70.1% (29/41)
of the median anticipated enrolment compared to 81.6%
(62/76) for non-rare trials and the proportion of trials in
rare diseases decreases as enrolment number (antici-
pated or actual) increases.
The proportion of rare disease trials with an industrial
lead sponsor, defined as ‘the organization or person who
oversees the clinical study and is responsible for analysing
the study data’. ClinicalTrials.gov [20], is slightly greater
(34.5% vs. 30.2%) than non-rare disease trials. The major-
ity of trials of either type are undertaken within a single
administrative region (US, Canada or the EU). However, a
higher proportion of rare disease trials are undertaken
across these administrative regions (8.1% vs. 4.4%) com-
pared to non-rare disease trials. Further, exploring individ-
ual countries as opposed to these administrative regions, a
Table 2 Characteristic of rare and non-rare disease clinical trials within the ClinicalTrials.gov registry








Year enrolment to protocol began, n (%)
Prior to 2006 455 (16.7) 2791 (13.2) 3.4 2 to 5
2006-2007 871 (31.9) 5121 (24.2) 7.6 6 to 10
2008-2009 859 (31.5) 5858 (27.8) 3.7 2 to 6
2010-2011 467 (17.1) 5315 (25.2) −8.1 −7 to −10
2012 and after 78 (2.9) 2018 (9.6) −6.7 −6 to −7
Overall status, n (%)
Completed 1169 (42.4) 8564 (40.2) 2.2 0 to 4
Not yet recruiting 15 (0.5) 1030 (4.8) −4.3 −4 to −5
Recruiting 372 (13.5) 6840 (32.1) −18.6 −17 to −20
Withdrawn 99 (3.6) 332 (1.6) 2.0 1 to 3
Active, not recruiting 638 (23.1) 2742 (12.9) 10.3 9 to 12
Terminated 379 (13.7) 1332 (6.2) 7.5 6 to 9
Suspended 36 (1.3) 154 (0.7) 0.6 0 to 1
Enrolling by invitation 51 (1.8) 335 (1.6) 0.3 0 to 1
Gender, n (%)
Female 116 (4.2) 1949 (9.1) −4.9 −4 to −6
Male 60 (2.2) 1042 (4.9) −2.7 −2 to −3
Both 2583 (93.6) 18338 (86.0) 7.6 7 to 9
Includes paediatric (<18), n (%)
Yes 546 (20.6) 2294 (11.1) 9.5 8 to 11
No 2106 (79.4) 18320 (88.9) −9.5 −8 to −11
Includes Elderly (>65), n (%)
Yes 2291 (86.4) 17157 (83.2) 3.2 2 to 5
No 361 (13.6) 3457 (16.8) −3.2 −2 to −5
Anticipated enrolment‡, n (%)
0-50 798 (61.7) 4556 (38.2) 23.5 21 to 26
51-100 280 (21.6) 2731 (22.9) −1.3 0 to −4
101-500 195 (15.1) 3767 (31.6) −16.5 −14 to −19
500+ 21 (1.6) 877 (7.4) −5.7 −5 to −6
Actual enrolment‡, n (%)
0-50 955 (71.4) 3570 (43.3) 28.1 25 to 31
51-100 211 (15.8) 1607 (19.5) −3.7 −1 to −6
101-500 158 (11.8) 2402 (29.1) −17.3 −15 to −19
500+ 14 (1.0) 672 (8.1) −7.1 −6 to −8
Lead Sponsor, n (%)
Industry 951 (34.5) 6437 (30.2) 4.3 2 to 6
NIH 72 (2.6) 602 (2.8) −0.2 0.5 to −0.8
US Federal 15 (0.5) 472 (2.2) −1.7 −1 to −2
Other 1721 (62.4) 13817 (64.8) −2.4 −1 to −4
Location, n (%)
US only 1720 (62.3) 12073 (56.6) 5.7 4 to 8
Canada only 83 (3.0) 1387 (6.5) −3.5 −3 to −4
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Table 2 Characteristic of rare and non-rare disease clinical trials within the ClinicalTrials.gov registry (Continued)
EU only 733 (26.6) 6938 (32.5) −6.0 −4 to −8
US/Canada 84 (3.0) 405 (1.9) 1.1 1 to 2
US/EU 93 (3.4) 333 (1.6) 1.8 1 to 3
EU/Canada 9 (0.3) 55 (0.3) 0 −0.1 to 0.4
US/EU/Canada 37 (1.3) 138 (0.6) 0.7 0.3 to 1
Number of countries,
n (%)
Single country 2442 (88.5) 19847 (93.1) −4.5 −3 to −6
2-3 countries 219 (7.9) 1057 (5.0) 3.0 2 to 5
≥4 countries 98 (3.6) 425 (2.0) 1.6 1 to 2
*Denominators exclude missing values. Missing data values [Rare (%), Non-Rare(%)] are: Year of enrolment [29(1.1),226(1.1)]; Study duration [361(13.1),2784(13.1)];
Ages [107(3.9),715(3.3)]; Enrolment [127(4.6),1147(5.4)].
‡Anticipated and Actual enrolment are mutually exclusive in ClinicalTrials.gov (Rare Anticipated [1294] vs. Actual [1338]; Non-Rare Anticipated [11931] vs.
Actual [8251]).
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multi-national (11.5% vs. 6.9%).
Design characteristics
Design characteristics of rare diseases trials differ to
non-rare diseases trials (Table 3). Centres (labelled as fa-
cilities in ClinicalTrials.gov) identify where the protocol
is being conducted. A lower proportion of rare disease
trials conducted the study protocol at a single centre
compared to non-rare trials (61.3% vs. 72.7%).
Rare disease trials are more likely to be early phase trials
(those reporting a phase 1 and/or 2 element), (72.5% vs.
38.5%). A lower proportion of rare disease trials employed
the N/A phase description (11.3% vs. 30.2%) which is
advised to be used for trials that do not involve drug or
biologic products although this is not enforced in Clinical-
Trials.gov [20]. The primary purpose of a rare disease trial
is generally treatment (91.2% vs. 79.3%) with the interven-
tion used tending to be a drug (79.9% vs. 55.8%).
The appointment of a Data monitoring committee
(DMC) is more common in rare disease trials (53.2% vs.
40.9%). They are also more likely to have a single group
assignment (63.0% vs. 29.6%), with no randomisation
(64.5% vs. 28.4%) and open label (78.7% vs. 52.2%). Rare
disease trials are also more likely to explore both safety
and efficacy endpoints in the same trial (63.2% vs. 45.9%).
Discussion
This analysis of ClinicalTrials.gov suggests that trials in
rare diseases differ from those of non-rare conditions.
Rare disease trials are more likely to have smaller target
sample size, more likely to be early-phase, more likely to
recruit to a single arm, more likely to be non-randomised,
and more likely to be unblinded. These results support
those of Kesselheim et al. and Mitsumoto et al. that have
explored orphan drug approval trials in the specialities of
cancer and neurology respectively [4,21]. Results from ourstudy add to current knowledge by including a wider array
of clinical studies, not just those completed and used in
application for drug approval, and by examining a number
of characteristics that have not been considered previously.
It has been argued that whenever possible standard
methodological approaches, such as the randomised con-
trolled trial, should be applied in the design and analysis of
a clinical trial [22]. However, due to the very limited pool
of eligible patients with rare diseases, evidence from good
quality randomised controlled trials is often absent for a
particular disease. The rarity of the disease makes enrolling
a sufficient number of participants inherently difficult.
A higher proportion of rare disease trials employ a
multi-centre design; potentially across multiple countries.
However, whilst there is an increased use of multi-centre
trials in rare diseases compared to non-rare diseases, they
are still predominantly single centred. This suggests there
is potential for important improvements to be made in the
numbers of patients recruited to rare disease trials. Fur-
ther cooperation between research facilities could greatly
improve research and the on-going development of
patient contact registries could also serve as powerful tools
for improving recruitment [23].
A larger proportion of rare disease trials enrolled paedi-
atric participants particularly in conjunction with adult
participants. That 67.9% of rare disease trials within the
orpha.net database had an age of onset given as neonatal,
infancy or childhood could go some way to explaining this
result. In general, eligibility criteria in rare disease trials
were less restrictive than in non-rare trials. Whilst we only
have eligibility criteria in terms of age and gender in the
ClinicalTrials.gov dataset the idea of the introduction of
participant heterogeneity needs to be carefully considered
in the analysis plan of any rare disease trials. Failure to
identify the most appropriate target population was found
to be a key feature of failed orphan marketing authorisa-
tions in both the EU and US [24,25].
Table 3 Design attributes of clinical trial within the ClinicalTrials.gov data set








Number of facilities, n (%)
Single facility 1671 (61.3) 15443 (72.7) −11.4 −9 to −13
2-3 facilities 333 (12.2) 2482 (11.7) 0.5 0 to 2
≥4 facilities 720 (26.4) 3315 (15.6) 10.8 9 to 13
Study phase, n (%)
Phase 0 15 (0.5) 166 (0.8) −0.2 0 to −0.5
Phase 1 410 (14.8) 1848 (8.7) 6.2 5 to 8
Phase 1/2 294 (10.7) 1014 (4.8) 5.9 5 to 7
Phase 2 1212 (43.9) 4747 (22.3) 21.7 20 to 24
Phase 2/3 83 (3.0) 601 (2.8) 0.2 0 to 1
Phase 3 287 (10.4) 3110 (14.6) −4.2 0 to −5
Phase 4 145 (5.3) 3398 (15.9) −10.7 −10 to −12
NA 313 (11.3) 6445 (30.2) −18.9 −17 to −20
Primary purpose, n (%)
Treatment 2451 (91.2) 16195 (79.3) 12.0 11 to 13
Prevention 87 (3.2) 1488 (7.3) −4.0 −3 to −5
Screening 1 (0.0) 86 (0.4) −0.4 −0.2 to −0.5
Supportive Care 39 (1.5) 844 (4.1) −2.7 −2 to −3
Health Services Research 7 (0.3) 446 (2.2) −2 −2 to −2
Educational/Counselling/Training 2 (0.1) 14 (0.1) 0.0 0 to 0
Diagnostic 75 (2.8) 917 (4.5) −1.7 −1 to −2
Basic Science 25 (0.9) 441 (2.2) −1.2 −1 to −2
Study has DMC†, n (%)
Yes 1211 (53.2) 7274 (40.9) 12.3 10 to 14
No 1066 (46.8) 10511 (59.1) −12.3 −10 to −14
Intervention model¥, n (%)
Single Group Assignment 1691 (63.0) 6134 (29.6) 33.5 32 to 35
Parallel Assignment 837 (31.2) 12466 (60.1) −28.9 −27 to −31
Crossover Assignment 140 (5.2) 1741 (8.4) −3.2 0 to −4
Factorial Assignment 14 (0.5) 411 (2.0) −1.5 −1 to −2
Intervention type‡, n (%)
Drug 2204 (79.9) 11891 (55.8) 24.1 22 to 26
Device 127 (4.6) 2620 (12.3) −7.7 −7 to −9
Procedure 269 (9.7) 2408 (11.3) −1.5 0 to −3
Biological 220 (8.0) 926 (4.3) 3.6 3 to 5
Radiation 112 (4.1) 476 (2.2) 1.8 1 to 3
Behavioural 47 (1.7) 2631 (12.3) −10.6 −10 to −11
Dietary Supplement 31 (1.1) 562 (2.6) −1.5 −1 to −2
Genetic 39 (1.4) 124 (0.6) 0.8 0 to 1
Other 176 (6.4) 2700 (12.7) −6.3 −5 to −7
Allocation¥, n (%)
Randomised 949 (35.5) 14958 (71.6) −36.1 −34 to −38
Non-randomised 1727 (64.5) 5937 (28.4) 36.1 34 to 38
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Table 3 Design attributes of clinical trial within the ClinicalTrials.gov data set (Continued)
Endpoint classification, n (%)
Efficacy Study 530 (22.0) 7454 (42.0) −20.0 −18 to −22
Safety/Efficacy Study 1521 (63.2) 8148 (45.9) 17.3 15 to 19
Safety Study 276 (11.5) 1154 (6.5) 5.0 4 to 6
Pharmacodynamics Study 9 (0.4) 282 (1.6) −1.2 −0.8 to −1.5
Pharmacokinetics Study 36 (1.5) 339 (1.9) −0.4 0.2 to −0.9
Pharmacokinetics/Dynamics Study 27 (1.1) 234 (1.3) −0.2 0.3 to −0.5
Bio-equivalence Study 5 (0.2) 90 (0.5) −0.3 0 to −0.5
Bio-availability Study 1 (0.0) 47 (0.3) −0.2 −0.2 to −0.3
Type of arms‡, n (%)
Experimental 1743 (84.3) 13063 (73.4) 10.4 9 to 12
Active comparator 458 (22.2) 7569 (42.8) −20.7 −19 to −23
Placebo comparator 343 (16.6) 4701 (26.6) −10.0 −8 to −12
Sham comparator 6 (0.3) 346 (2.0) −1.7 −1 to −2
No Intervention 73 (3.5) 1908 (10.8) −7.3 −6 to −8
Other 84 (4.1) 111 (6.3) 3.4 3 to 4
Blinding, n (%)
Open 2137 (78.7) 10967 (52.2) 26.6 25 to 28
Single 89 (3.3) 2680 (12.8) −9.5 −9 to −10
Double 488 (18.0) 7370 (35.1) −17.1 −15 to −19
*Denominators exclude missing values. Missing data elements [Rare(%), Non-Rare(%)]: No. of Facilities [35(1.3),89(0.4)]; Primary purpose [72(2.6),898(4.2)]; Study
has DMC [482(17.5),3544(16.6)]; Intervention model [77(2.8),577(2.7)]; Allocation [83(3.0),434(2.0)]; Endpoint Classification [354(12.8),3581(16.8)]; Type of arms [692
(25.1),3650(17.1)]; Blinding [45(1.6),312(1.5)].
†Data Monitoring Committee.
‡Studies can belong to multiple categories.
¥42% of studies labelled as single arm trials were missing allocation information. Whilst some missing data is inferred (see methods section) the trials still missing
allocation information are predominantly single-arm trials but missing group data. This allows there to be more single group assignment trials than there are
non-randomised trials for the non-rare disease dataset.
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disease clinical trials are still frequently small, single arm
studies. Concerns have been raised over the quality of
evidence obtained from such studies [26,27]. It is argued
that even in rare disease trials, where we cannot provide
a large quantity of evidence, researchers should still
attempt to provide good quality evidence [26]. Blinded,
randomised controlled trials are classed as the gold
standard for clinical trials. Whilst not straight-forward
to perform in rare diseases, these standards can still
often be achieved. Recent reviews have summarised
many alternative trial designs that can provide adequate
and well-controlled data for rare disease trials [28,29].
Of course, design recommendation for rare disease trials
such as Bayesian methods [30] and adaptive randomisa-
tion [31] are subtle and not identifiable in ClincalTrials.
gov and further analysis of published studies would be
required to explore if such recommendations have been
implemented.
A higher proportion of rare disease trials explored
drug and biological interventions than non-rare diseases
trials. One possible explanation is the 1983 OrphanDrug Act (ODA) in which the term "orphan drug" refers
to a drug or biologic. It has been highlighted that the
ODA provides a shelter for many biologic treatments as
market exclusivity provides a surrogate form of patent.
Other legislation, such as the Humanitarian Device Ex-
emption within the Safe Medical Devices Act of 1990,
exists to support development of other interventions in
rare diseases [32]. Despite these legislative incentives few
researchers have explored alternative interventions
through clinical trials.
The overall status of rare disease trials shows a pro-
portionately larger number have been terminated, with-
drawn or suspended. A comprehensive analysis of why
this is the case would be a useful aid for future re-
searchers planning rare disease clinical trials and poten-
tially prevent wasted resources. It is estimated that only
10% of rare diseases have an available treatment [33]. In
fact, in our study we found that only 9.5% of possible
‘rare disease’ MeSH terms identified had an associated
clinical trial which corresponds well with this finding.
Even for rare diseases with licenced orphan medicinal
products, these treatments can still be improved and
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ical evidence and lack of efficacy data for these products
[8,34]. Joppi et al. reflect that “…nearly all the currently
estimated 7,000 rare diseases, with approximately 250
new diseases described annually, still await treatment”,
as such, the medical need for appropriate clinical
research in rare diseases remains high.
Limitations
Numerous limitations to this study need to be noted.
Firstly our categorisation of rare and non-rare trials relied
on conditions being submitted as MeSH terms. Whilst this
is recommended by ClinicalTrials.gov, it is not enforced.
Approximately 30% of studies were instantly excluded be-
cause we could not map conditions to MeSH Id’s. Of the
11,959 rare disease terms identified, we could only match
54% to MeSH Id’s. Better application of text matching rou-
tines and the use of clinical experts could improve this
percentage. A potential consequence is that a number of
false negative results may be present in the non-rare dis-
ease trial dataset; their correct categorisation could help
improve the robustness of this characterisation study.
However, taking a random sample of 50 trials from the
non-rare dataset we did not find any false-negative results.
Thus, we believe that this is unlikely to introduce any bias
into the finding. The use of standard vocabulary for condi-
tions submitted to ClinicalTrials.gov could facilitate future
research.
Using both US and EU rare disease sources may also
limit this study as definitions of rare disease differ in these
regions. However, there is likely a large crossover of condi-
tions regardless of regions. Taking a random sample of 50
trials from the rare disease data set found only 4 (8%) trials
that were not listed as rare in both the US and EU. These
4 trials listed the conditions of epithelial ovarian cancer,
compartment syndrome, photosensitive epilepsy and focal
segmental glomerulosclerosis. They are all listed as rare in
the ClinicalTrials.gov registry but prevalence for these
conditions was not confirmed in the EU orpha.net data-
base [3].
Califf et al. describe a number of limitations to the
ClinicalTrials.gov dataset [12]. Firstly, ClinicalTrials.gov
does not register all trials. Registries such as Clinical-
TrialsRegister.eu can also be used. Confirmation of tem-
poral trends in the ClinicalTrials.gov dataset may need
to be corroborated across registries. This is particularly
true for specialist datasets; if large research institute
register future studies in a different database this could
have large implications on the identification of trends.
Secondly, data elements can be missing or unavailable
due to changes in the ClinicalTrials.gov registry defini-
tions, statutory requirements or simply not entered by
data submitters. Further to missing data elements, data
provided can also be inconsistent or inaccurate. Forexample a number of trials reported with single arm as-
signment had also reported a crossover, factorial or paral-
lel intervention model. Furthermore, we did not explore
the details behind the labels provided for each trial and we
recognise that there may be inaccuracies in definitions
such as ‘randomized’ or ‘blinded’. Causes for this may be
the expertise of data submitters or a lack of suitable con-
straints on the data being submitted to ClinicalTrials.gov.
Missing data, inconsistencies, and inaccuracies can impact
the quality of this, and any other, characterisations of tri-
als. However, we believe that these issues are likely to
introduce random error rather than bias since the issues
are likely to be distributed similarly across rare and non-
rare disease trials.
It is also worth pointing out the strengths of this ana-
lysis in that we have provided one of the largest and
most complete comparative surveys of rare disease clin-
ical trials to date.
Conclusion
ClincalTrials.gov and the AACT database can help us
characterise clinical research in rare diseases. With the
Food and Drug Administration (FDA) and EMA provid-
ing significant support for rare disease research it is crit-
ical to understand how research is implemented to help
identify where potential improvements can be made.
The ClinicalTrials.gov dataset shows that trials in rare
diseases use fewer participants and have longer duration
as might be expected. However, our study also shows
that rare disease trials are less likely to use blinding and
randomisation than trials in other areas. These are gen-
erally regarded as hallmarks of high-quality clinical trial
design and this raises concerns over the quality of evi-
dence being supplied by rare disease trials. With higher
termination rates for these trials, additional research is
required to identify ways to improve the quality, as well
as the quantity of rare disease trials.
What this paper adds
What is already known on this topic?
The evaluation of treatments for rare diseases presents a
number of challenges for trial practitioners, regulators and
policy makers. Within certain clinical specialities rare dis-
ease trials have been found to be smaller and to tend to
use nonrandomized, unblinded designs compared to trials
in non-rare conditions.
What this study adds
This study contrasts rare and non-rare diseases clinical
trials across a broader range of characteristics than pre-
viously seen in the literature. Trials in rare and non-rare
conditions differ in methodological approach including
quantifiable differences in the reported use of random-
isation, blinding and data monitoring committees. Rare
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minated than those in non-rare conditions.Availability of supporting data
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